|
|
 |
|
Viewing report
|
|
|
|
Biosimilars: A Physician's Perspective
Industry Standard Research (ISR), June 2010, Pages: 28
To say the environment around biosimilars is fluid would be an understatement. With fluidity comes uncertainty and with uncertainly comes opportunity. Many industry pundits are evaluating the biosimilar market by taking a big picture, macro assessment of the regulatory, clinical development, and commercialization issues. Industry Standard Research (ISR) took a focused approach to answering a few pointed questions around the potential prescribing of biosimilars. The publisher took this approach because of the fluid nature of the environment and because regardless of the nascent legislation recently enacted in the United States, or the forthcoming plan from the FDA, and the relative low adoption of biosimilars in Europe; they believe that physicians/ prescribers will be at the strategic center of biosimilar success or failure.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
|
|
|
|
